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Abstract
To understand whether any human-specific new genes may be associated with human brain functions, we computationally
screened the genetic vulnerable factors identified through Genome-Wide Association Studies and linkage analyses of
nicotine addiction and found one human-specific de novo protein-coding gene, FLJ33706 (alternative gene symbol
C20orf203). Cross-species analysis revealed interesting evolutionary paths of how this gene had originated from noncoding
DNA sequences: insertion of repeat elements especially Alu contributed to the formation of the first coding exon and six
standard splice junctions on the branch leading to humans and chimpanzees, and two subsequent substitutions in the
human lineage escaped two stop codons and created an open reading frame of 194 amino acids. We experimentally verified
FLJ33706’s mRNA and protein expression in the brain. Real-Time PCR in multiple tissues demonstrated that FLJ33706 was
most abundantly expressed in brain. Human polymorphism data suggested that FLJ33706 encodes a protein under
purifying selection. A specifically designed antibody detected its protein expression across human cortex, cerebellum and
midbrain. Immunohistochemistry study in normal human brain cortex revealed the localization of FLJ33706 protein in
neurons. Elevated expressions of FLJ33706 were detected in Alzheimer’s brain samples, suggesting the role of this novel
gene in human-specific pathogenesis of Alzheimer’s disease. FLJ33706 provided the strongest evidence so far that human-
specific de novo genes can have protein-coding potential and differential protein expression, and be involved in human
brain functions.
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Introduction
Many mechanisms for the origination of new genes are known,
such as tandem gene duplication, retrotransposition, exon
shuffling and gene fusion [1–5]. By these mechanisms, the
origination of new protein coding genes involved ‘‘mother’’ genes
that served as blueprints for the new genes. However, recent
comparative genomic analysis identified a few ‘‘motherless’’ or de
novo genes in fly and yeast [6–9], which originates from non-coding
DNA sequences. It is of great interest to ask whether the human
genome also encodes such genes which might contribute to unique
human phenotype.
Recently Toll-Riera et al identified in silico 15 de novo human
genes which seem to have emerged after the split of primates and
rodents [10]. However whether these de novo genes encode proteins
is unclear due to the lack of protein evidence. More recently
Knowles and McLysaght identified in silico three human-specific de
novo genes supported by peptides from high-throughput mass
spectrum data [11]. These studies, although tremendously
interesting, are lacking in two aspects. First, there is no solid
protein evidence so far for any of the de novo genes identified—
high-throughput mass spectrum data alone as protein evidence
can have limitations, as commented by Siepel [12]. Second, none
of these genes has been linked to human specific phenotype. Could
any de novo genes be associated with human unique biology,
especially to brain functions?
In our work, we were interested in finding de novo genes associated
withnicotine addiction. We took advantage of the recently available
high-throughput data from genome-wide association studies
(GWAS) and data from the more traditional linkage analyses.
Unlike candidate gene association studies that usually start with a
known gene, GWAS and linkage analyses are hypothesis-free and
thus can link previously uncharacterized genes to addiction. Despite
the great potentials, current GWAS results are under-analyzed and
under-utilized. There is a need for computational protocols to sift
through the GWAS results for interesting genes.
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Identification of FLJ33706 from GWAS and linkage
analyses
Here we carefully re-analyzed results from two published
GWAS [13,14] and two linkage analyses [15,16] for nicotine
addiction and looked for genes that (i) show statistical significance
in both GWAS and both linkage analyses; and (ii) have a complete
Open Reading Frame (ORF) that has no identifiable homologues
in other species. We found an interesting gene, FLJ33706
(alternative gene symbol C20orf203). Both GWAS identified
rs17123507, an SNP located in the 39UTR of FLJ33706,a s
significantly associated with susceptibility to nicotine addiction
[13,14]. Both linkage studies also implicated this region in ‘heavy-
smoking quantitative trait’ in individuals of European ancestry
[15,16]. These genetics data established the genomic region of
FLJ33706 as one of the 10 ‘convergent susceptible points’ for
nicotine addiction [16]. However, FLJ33706 was not directly
reported as a candidate gene to explain the genetic vulnerabilities
in any of the four studies, and to date, FLJ33706 remains an un-
studied gene. In the next steps of our work, we demonstrated that
FLJ33706 is an interesting human-specific de novo protein-coding
gene. We traced how this fascinating gene originated out of
noncoding DNA sequence and experimentally studied its popula-
tion genetics, mRNA expression, protein expression, and cellular
localization.
Origination of FLJ33706 out of noncoding DNA
FLJ33706 is located on Chromosome 20q11.21. Little is known
about this gene: it has no publication, no detectable protein
domain by InterPro [17], and no BLAST hit to any other known
protein sequences. Four mRNAs and four spliced ESTs in
GenBank map to this locus, supporting the expression of
FLJ33706 at the transcription level. The UniProtKB/TrEMBL
database provided a computationally translated ORF and label it a
‘‘predicted protein’’ (Accession Number: B8JHY2_HUMAN)
[18], but the UCSC genome browser and NCBI Entrez Gene
database marked it as a ‘‘non-coding RNA’’ [19,20].
We re-sequenced all five available EST clones (see details in
Materials and Methods) and inferred the gene structure of
FLJ33706 (GenBank Accession Number: GU931820). The whole
locus covers a 42.3 Kb genomic region, encoding a 5,093 bp
polyadenylated transcript separated by five standard introns
marked with GT-AG splicing junctions. A putative open reading
frame (ORF) with 194 codons is located in exons 3 and 4
(Figure 1).
The 44-way vertebrate syntenic genome-alignment tracks of the
UCSC browser [19] showed that the DNA segment where
FLJ33706 gene is located emerged in the eutherian mammals,
since it is completely absent from all outgroups ranging from
marsupials to lamprey (Supplementary Figure S1). Although
this locus predated the radiation of modern mammals, the full
splicing structure appeared at a much later time. Specifically,
syntenic alignments flanking five splicing junctions (Figure 2)
revealed that non-primate mammals only encode the first standard
splicing junction. For the remaining four introns, non-primate
mammals used non-standard junctions if they spliced these regions
out at all. Most likely the last four introns were not spliced.
Furthermore, only hominoid used GT-AG for the third intron,
while the possible ancestral states shared by rhesus monkey and
mouse lemur armadillo is GA-AG (Figure 2). Such difference
across the splicing junctions indicated that the FLJ33706 locus
must have undergone multiple-step changes in order to acquire the
present relatively complex gene structure in human.
Manual inspection of the gene structure and vertebrate genome
comparisons showed that newly inserted repeat elements,
especially Alu sequences, contributed substantially to the formation
of the first coding exon and the six standard splice junctions on the
branch leading to the hominoid (Figure 1, 2). Specifically, the
splicing acceptor of the second intron, the donor and acceptor of
the fourth intron, and the splicing donor of the last intron were
derived from Alu sequences. In addition, Alu contributed to 71% of
the first coding exon and 16% of the total ORF. This finding is
consistent with other reports that transposable elements can
contribute to the creation of both protein-coding regions and
splice junctions [10,21].
The putative ORF of FLJ33706 is human-specific. Sequence
alignments across multiple primates including human, chimp,
gorilla, orangutan, rhesus monkey and marmoset showed that the
FLJ33706 ORF emerged only on the human lineage after the
divergence of human and chimpanzee by the introduction of five
point mutations, including two important mutations that escaped
two ancestral frame-disrupting features, TAG—.TGG at amino
acid position 28 and GGAA—.G-AA at amino acid position 106
(Figure 3). Chimpanzee seems to share the ancestral status for
both of these sites. This is unlikely to be an artifact caused by
sequencing error because the sequencing quality of the chimpan-
zee genome in this region is quite high. For example, TAG is
supported by six chimp reads (Supplementary Figure S2).
Thus, FLJ33706 is likely a bona fide human-specific de novo protein-
coding gene.
FLJ33706 transcription is enriched in brain regions
As aforementioned, eight spliced mRNA and EST sequences
support the transcription of FLJ33706. These transcripts were
mainly cloned from brain libraries, suggesting brain-enriched
expression of FLJ33706. No mRNA or EST in Genbank from any
other species could be reliably mapped to the orthologous genomic
locus or to FLJ33706—only one unspliced Sus scrofa EST
(BI343741) could be mapped to the first 39 untranslated region
Author Summary
For decades, gene duplication, retrotranspositions and
gene fusions were believed to be major ways to increase
gene number. All involve ‘‘mother’’ genes as the ‘‘building
blocks’’ for new genes. However, several recently identified
‘‘motherless’’ genes challenged the idea in that some
proteins might have emerged de novo from ancestral non-
coding DNAs. Did any such genes emerge in human after
the divergence from chimpanzee? If yes, such genes might
help understand what makes us human. Here we report
the first experimentally verified case of a human-specific
protein-coding gene, FLJ33706 (alternative gene symbol
C20orf203), that originated de novo since the divergence of
human and chimpanzee. FLJ33706 was formed by the
insertion of repeat elements, especially Alu sequences, that
contributed to the formation of the first coding exon and
six standard splice junctions, followed by two human-
specific substitutions that escaped stop codons. The
functional protein-coding features of the FLJ33706 gene
are supported by population genetics, transcriptome
profiling, Western-blot and immunohistochemistry assays.
Data suggest that FLJ33706 may be involved in nicotine
addiction and Alzheimer’s disease. FLJ33706 provided the
strongest evidence so far that human-specific de novo
genes can have protein-coding potential and be involved
in human brain functions.
Human-Specific de novo Protein-Coding Gene
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a databset GSE7094 which profiled five tissues (cortex, fibroblast,
pancreas, testis and thymus) in rhesus monkey. Re-analysis of the
data showed low expression signal in Rhesus Macaque (normalized
expression intensity 2.2,2.7). In summary, both EST and
microarray data indicated that FLJ33706 has low or non-existent
transcription in non-hominoid mammals.
We further experimentally quantified FLJ33706 mRNA levels
in eight human peripheral tissues and eight human brain regions
using the TaqMan technique with FAM-labeled probe hybridized
across exon3 and exon4. We observed that FLJ33706 mRNA was
significantly enriched in the brain, especially in regions implicated
in cognitive abilities (Figure 4, Supplementary Table S1).
The mRNA expression levels of FLJ33706 in cortex and
hippocampus were comparable to those of the neuronal specific
isoform of brain-derived neurotrophic factor (BDNF1), although
lower than those of the calcium activated isoform (BDNF4) [23].
The biased tissue expression patterns of FLJ33706 and the
comparable expression levels between FLJ33706 and BDNF1
provided further support that FLJ33706 might be a functional
gene.
FLJ33706 encodes a bona-fide protein expressed in
human brain
To explore whether or not FLJ33706 may have protein coding
potential, we first performed population genetics analysis of 90
individuals including all major sub-populations (Supplementary
Table S2) to investigate whether this putative coding region,
especially the nonsynonymous sites, was under more constraint.
We sequenced the coding region and 1 Kb flanking regions of the
FLJ33706 locus in the 90 individuals. No frame-disrupting
mutation was found, which suggested some degree of protein-
level constraint. Moreover, the nonsynonymous sites showed the
strongest constraint (nucleotide diversity p of 5610
25)( Table 1,
Supplementary Table S2). By contrast, synonymous sites had
an order of magnitude larger p (4610
24). We further tested
whether this difference departed from neutral assumptions using
Hudson’s formula [24]. Despite of the small size of this putative
protein, the comparison still yielded a marginally significant p of
0.1, which suggested that the nonsynonymous sites did evolve
under more constraint. Finally, the whole coding region had lower
nucleotide diversity p compared to its immediate flanking regions,
the second intron or the 39 UTR (Supplementary Figure S3).
In summary, population genetics analysis suggested that FLJ33706
potentially encoded a protein under purifying selection.
However, protein-coding potential of FLJ33706 suggested by
population genetics analysis was still not conclusive. To explore
whether or not FLJ33706 actually encodes the 194-codon protein,
we developed FLJ33706-specific antibody and performed Western
blot analyses. We designed a 17-amino-acid antigenic peptide,
CTSKAQRVHPQPSHQRQ, corresponding to the non-repeti-
tive region (residues 68–83) of the FLJ33706 putative protein plus
a cystine at the N-terminus to facilitate conjugation to an adjuvant.
The epitope sequence had no homology with the coding peptides
of Alu or other repeat elements and could not match any other
proteins in NCBI NR database [20]. This peptide was synthesized
Figure 1. Gene structure of FLJ33706, a human-specific de novo protein-coding gene. Data for the tracks ‘Spliced Human EST’ and ‘Human
mRNA’ was extracted and assembled from UCSC Genome Browser. We re-sequenced all available mRNAs and spliced ESTs, shown in the track ‘Re-
sequenced ESTs/mRNAs’. On the basis of these data, we inferred gene structure for this novel gene, with six exons marked as ‘1,6’ in the track
‘FLJ33706 Gene Structure’. The exons partially derived from re-sequenced data were highlighted in green. An ORF with two short coding exons
located at exon 3 and exon 4 was identified to encode a 194-amino-acid-long peptide (track ‘Open Reading Frame (ORF)’). Newly inserted
transposable elements, especially Alu sequences, contributed substantially to the formation of the first coding exon and six standard splicing
junctions on the branch leading to human and chimpanzee, marked as ‘a,f’ in the track ‘FLJ33706 Gene Structure’. All repeat elements in this region
were shown in track ‘RepeatMasker’, extracted from UCSC Genome Browser. Coding exons in tracks ‘Spliced Human EST’, ‘Human mRNA’ and
‘FLJ33706 Gene Structure’ were represented by higher vertical bars, while UTR regions and intronic regions were represented by lower vertical bars.
Size scales were added in the figure to give benchmarks for gene sizes. Tracks with different size scales were separated by horizon lines.
doi:10.1371/journal.pcbi.1000734.g001
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was produced from a responsive animal after initial and boosting
immunizations. Using this anti-serum as the primary antibody,
Western blot assay detected a band with apparent molecular mass
of 22 kDa, which was consistent with the predicted molecular
weight of the FLJ33706-encoded protein, in human brain cortex
(Figure 5A). This band was not present when pre-immune serum
was used or when the antibody was pre-absorbed with excess
synthetic FLJ33706 antigenic peptides (Figure 5A) [25]. We
further expressed FLJ33706 recombination protein with His-Tag
in E. coli expression strain to evaluate the specificity of FLJ33706
antibody in Western blot assays. As expected, the band with
apparent molecular mass of 22 kDa was detected in transformed
E. coli samples by both His-Tag specific antibody and the
aforementioned FLJ33706 antibody, but not in wild-type E. coli
samples (Figure 5B). These results provided verification of the
antibody.
Using this verified FLJ33706-specific antibody, we studied the
expression and localization of FLJ33706. We first identified the
expression of FLJ33706 in three human brain regions: cortex,
cerebellum and midbrain. The specific band could be detected in
all human samples but not mouse samples as negative controls
(Figure 5C). We then performed within-species studies using
cortex samples from seven different human brains and observed
FLJ33706 expression in all samples, with some variation in protein
expression levels (Figure 5D). We further performed immuno-
histochemistry studies of FLJ33706 by high-resolution confocal
imaging in normal human cortex slides stained with beta-tubulin-
III. The clear co-localization signals indicated cellular localization
of FLJ33706 protein in human neurons (Figure 6).
FLJ33706 is up-regulated in Alzheimer’s disease (AD)
brains
Could FLJ33706 be involved in other human brain-related
pathogenesis such as AD? As a preliminary study, we measured
the transcriptional level of FLJ33706 in the middle fontal gyrus
(Brodmann area 46) of 20 AD brains and 18 normal brains using
the TaqMan-based Real-Time PCR system. The expression level
of FLJ33706 in AD brains was significantly elevated (Mann
Whitney Test, p=0.027) (Supplementary Figure S4). This
finding implicated FLJ33706 as a potential candidate gene for
studying the human-specific pathogenesis underlying Alzheimer’s
disease [26].
Discussion
FLJ33706 represents a human-specific de novo protein-
coding gene with the strongest evidence so far
In previous works, only one of the de novo genes in yeast and
three in human had some high-throughput mass spectrum
evidence of protein coding potential [7,11]. However high-
throughput mass spectrum data can be noisy and peptide
identification is dependent on the algorithms and search
parameters. Our results on FLJ33706 provided the strongest
experimental evidence so far of protein expression and differential
protein expression of a de novo gene.
Figure 2. Syntenic alignments of five flanking splicing junctions of FLJ33706. (Top) The syntenic alignments of five flanking splicing
junctions of FLJ33706 among 13 species were shown, in which intron regions were highlighted in blue boxes and splicing sites were highlighted in
red. Lineage-specific insertions, unalignable bases in the gap region and uncertain regions were were marked as ‘-’, ‘=’ and ‘N’, respectively.
(Bottom) The splicing sites from 8 species were shown in the context of the phylogeny. Red ‘Y’ represents presence of the splicing signal and blue
‘N’ represents absence. Exons and introns are not drawn to scale.
doi:10.1371/journal.pcbi.1000734.g002
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in human, and observed two frame-disrupting features in
chimpanzee that would prevent this ORF from being translated.
Moreover, these two features are shared by multiple non-human
primates, which suggest that this ORF did not exist in the ancestral
status. Identification of ancestral frame-disrupting features is a
common strategy to identify species-specific de novo proteins
[27,28]. Ideally, we would want to use chimpanzee tissues as
negative controls in the Western blot assays. Unfortunately, it
proved impossible for us to obtain chimpanzee postmortem
samples, especially brain regions, due to our limited resources.
Despite this, all our current evidence supports FLJ33706 as a
human-specific de novo protein.
The recently published genome-wide scan by Knowles and
McLysaght identified three human-specific de novo protein-coding
genes [11] but failed to identify FLJ33706. The authors used the
automated annotations by Ensembl (version 47) which incorrectly
annotated FLJ33706 as having an orthologous protein-coding
gene in chimpanzee (ENSPTRG00000030588). However, as we
described before, the chimpanzee locus consists of two frame-
disrupting features. In order to make an intact ORF, Ensembl’s
automatic annotation pipeline made these two features (‘‘TAG’’
and ‘‘G’’) as extra tiny introns inside the frame. Such events are
extremely unlikely because very few human introns are smaller
than 80 bps [17]. In other words, misannotation of Ensembl have
likely resulted in the failure of Knowles and McLysaght [11] to
discover FLJ33706.
Siepel commented on the importance of distinguishing true de
novo genes from genes that were functional in ancestral genomes
but lost in multiple lineages [12]. In the case of FLJ33706,t h e
latter scenario is highly unlikel y .F i r s t ,w et r a c e dt h ew h o l e
evolutionary history of FLJ33706 across vertebrates and found
that only human has an intact ORF. If this gene were functional
in ancestral mammals, then there would have to be too many
independent gene loss events, which is highly unlikely. Second,
parallel loss for the same locus in different lineages requires that
this locus be in some sort of mutational hot spot [12]. Our
population survey showed that FLJ33706 does not have an
unusually high level of polymorphism (h ,0.001 which is
comparable to the genome-wide background level of 1610
23)
[29]. Thus, at least in human, this locus is not generally
permissive for mutation. In summary, FLJ33706 is a bona fide de
novo gene.
FLJ33706 has the proposed features of de novo genes
Siepel proposed a few features of de novo genes [12]: de novo gene
products are usually small with less than 200 amino acids because
of the difficulty in de novo gene origination; they are often derived
from the antisense strand of a pre-existing gene so that they might
be able to re-use the transcriptional context; repeats elements
Figure 3. Alignment of human FLJ33706 ORF with orthologous genomic sequences in four other primates. For each position in human
FLJ33706 ORF, the corresponding orthologous genomic sequences in chimpanzee, gorilla, orangutan and rhesus monkey were aligned to human
reference to identify the types of variations. Only amino acid sites with at least one variation among ‘‘Human-Human’’ (SNP), ‘‘Human-Chimpanzee’’,
‘‘Human-Gorilla’’, ‘‘Human-Orangutan’’ or ‘‘Human-Rhesus’’ were shown. Identical sites were shown as black dots while divergent sites were shown in
red (non-synonymous mutations), green (synonymous mutations) and blue (SNP). Two human-specific mutations that escaped stop codons were
highlighted by black frames. Amino acids with non-synonymous variations were highlighted in red while synonymous variations in blue. All
sequencing data in this study were traced and manually checked to ensure reliability.
doi:10.1371/journal.pcbi.1000734.g003
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the gene hydra in D.melanogaster [8]. FLJ33706 showed similar
features: it encodes a small protein of 194 amino-acids; although it
is not derived from the antisense strand of another gene, it is
located in a gene-dense region with two other genes in its
immediate flanking regions (,30 kb distance) and thus the local
chromatin structure might be open, which renders transcription
more permissive; and finally, the primate-specific repeat element,
Alu, contributed to origination of multiple introns and a portion of
the coding region.
Non-neutral evolution of FLJ33706
The small protein size and human-specific nature of FLJ33706
resulted in insufficient statistical power for many evolutionary tests.
Nevertheless, we were still able to detect that this locus deviates
from neutral expectation. Polymorphism distribution across
Figure 4. FLJ33706 mRNA expression in peripheral tissues and brain regions. FLJ33706 mRNA levels were measured in eight peripheral
tissues and eight brain regions using TaqMan-based Real-Time PCR system. Relative quantity was calculated using expression means of human
leukocyte as references (Fold=1.0). FLJ33706 had relatively higher expression levels in brain regions (highlighted in red) than in peripheral tissues
(shown in white). The expression levels of human BDNF1 and BDNF4 (shown in blue bars) in cortex (BDNF1_CTX, BDNF4_CTX) were also compared
with those of FLJ33706 using also leukocyte FLJ33706 expression as a reference.
doi:10.1371/journal.pcbi.1000734.g004
Table 1. population genetics statistics of FLJ33706.
Locus Length (bp)
Number of Single Nucleotide
Polymorphisms h/site p/site
CDS (Whole) 585 4 1.19E-03 1.50E-04
CDS (Synonymous) 151 2 2.29E-03 4.30E-04
CDS (Non-Synonymous) 434 2 8.00E-04 5.00E-05
59UTR 263 2 1.32E-03 8.00E-05
39UTR 1,177 8 1.18E-03 4.50E-04
Intron 830 8 1.67E-03 1.00E-03
Population genetics analyses of 90 individuals were performed and population genetics statistics of FLJ33706 were shown. CDS: coding sequences.
doi:10.1371/journal.pcbi.1000734.t001
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ymous sites, UTR and introns suggested that FLJ33706 is subject
to functional constraint. Base-level conservation score calculated
by PhyloP [30] based on placental mammal genome alignment
showed that introns 2 and 3 are enriched with fast-evolving
nucleotides (Supplementary Figure S5) which suggested that
the emergence of these two introns in primate might be driven by
positive selection.
Although this locus existed since at least 80 million years ago
(the time for mammalian radiation), its complete splicing struc-
ture encoding five standard splicing junctions is younger than
38 million years (human and rhesus monkey divergence time)
[www.genome.gov/Pages/Research/Sequencing/SeqProposals/
PrimateSEQ012306.pdf]. It is possible that FLJ33706 is already
transcribed in the hominoid ancestor at low abundance. Thus,
human FLJ33706 protein may have evolved out of a noncoding
RNA which evolved out of noncoding DNA.
Furthermore, FLJ33706 are mainly expressed in human brain,
with more than two folds higher expression in cortex compared to
testis. By contrast, its ortholog in rhesus monkey seems to have low
expression intensity in major tissues and non-differential abun-
dance between cortex and testis. Thus, FLJ33706 not only
acquired more complicated gene structure, but refined its
expression profile in the human lineage.
FLJ33706 is involved in human-specific brain
pathogenesis
As mentioned above, an addiction-linked SNP rs17123507 is
located in the gene region of FLJ33706, confirmed by two GWAS
and two linkage analyses. To clarify whether this SNP is the
‘causative’ SNP of addiction susceptibility within its haplotype
block, we used HapMap data to identify all SNPs showed strong
linkage disequilibrium (r2$0.8) with rs17123507. rs17123507 was
the only one located in the exon region (39UTR) of FLJ33706
among a tandem set of putative binding sites of let-7, a brain-
expressed miRNA implicated in neuron specification [31]. All
other SNPs were located in intronic or intergenic regions without
any annotations or detectable signals of regulatory elements. Thus,
rs17123507 was the most possible ‘causative’ SNP within the
haplotype block that convey addiction susceptibility.
We also found that FLJ33706 expressions were up-regulated in
AD brains. Thus FLJ33706 is likely involved in a range of human
brain functions and pathogenesis. However, exactly how
FLJ33706 affects human brain functions and exactly why both
addiction and AD might be implicated remain unknown and are
interesting questions for future studies.
A model for identifying interesting candidate genes from
GWAS data
GWAS provides invaluable links between genes and diseases/
phenotypes at high throughput. During the past few years, GWAS
have identified numerous genetic variations that contribute to
susceptibilities underlying various complex diseases. However,
GWAS data is often under-analyzed and poorly interpreted. Our
work provides a computational protocol for identifying and
studying interesting candidate genes from GWAS of not only
addiction, but also other diseases and phenotypes. On the other
hand, the studies of the functions of novel genes are time-
consuming and often involve much guesswork. Our work
demonstrated the feasibility of integrating the rapidly accumulat-
Figure 5. Western-blot assays to determine the protein expression levels of FLJ33706. (A) A specific band with molecular mass of about
22 kDa in SDS-PAGE, which was consistent with the predicted molecular weight of FLJ33706 putative proteins, was detected in the Western-blot
assay. The band could not be detected in pre-immune control and peptide competition control. Pre: pre-immune reaction assay; Ab: FLJ33706
antibody assay; Pep: peptide competition assay. (B) E. coli samples before and after the transformation of FLJ33706 recombination plasmids were
assayed by Western blot using (a) His-tag specific antibody and (b) anti-FLJ33706. FLJ33706 expression in human cortex was shown in (c) as the
control. Before: E. coli samples before the plasmid transformation; After: E. coli samples after the plasmid transformation. (C) The specific band can be
detected in all human brain regions, but not in mouse brain regions used as controls. H-CTX, M-CTX: human/mouse cortex; H-MID, M-MID: human/
mouse midbrain; H-CER, M-CER: human/mouse cerebellum; (D) FLJ33706 expression can be detected in different human individuals. 384, 994, 275,
995, 705, 710, 1277: individual IDs. 22KD: theoretical molecular weight of FLJ33706 protein; 42KD: molecular weight of beta-actin protein as
endogenous control. In A and C, antibodies for FLJ33706 and endogenous control were mixed in Western assays.
doi:10.1371/journal.pcbi.1000734.g005
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with human diseases and phenotypes.
Our work is a good example of how computational screening of
existing biological data can lead to interesting, experimentally
verifiable discoveries. Although we spent much effort to experi-
mentally verify the gene and protein expression of FLJ33706, the
most novel part of our contribution is in fact how we had
computationally selected this hidden gem from the human genome
in the first place. More specifically, our work can serve as a model
for future studies of de novo species-specific protein-coding genes
that would start from computational and evolutionary analyses
similar to what we have done here.
In conclusion, our data provided the strongest evidence so
far for a human-specific de novo protein and its association with
human brain functions. It had been well accepted that protein
amino acid changes, protein family expansion and shrinkage, and
cis-regulatory element changes contributed to human brain
evolution [32]. Our study suggested that motherless new genes
may be an under-appreciated source of new brain functions.
Materials and Methods
Ethics statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. Human tissues were obtained from
Department of Pathology, Johns Hopkins Medical School and the
NICHD Brain and Tissue Bank, which have been approved by the
Institutional Review Board of Johns Hopkins Medical School and
University of Maryland, Baltimore, Maryland, USA. All animals
were handled in strict accordance with good animal practice as
defined by the relevant national and/or local animal welfare
bodies, and all animal work was approved.
Sample preparations
Brain tissues from 20 Alzheimer’s disease (AD) patients and 18
non-AD control individuals were obtained post mortem (Depart-
ment of Pathology, Johns Hopkins Medical Institutions). For each
individual sample, a portion of medial frontal gyrus (Brodmann
area 46) was prepared for extraction of total RNA. Frontal cortex,
midbrain, and cerebellum brain regions were obtained from the
NICHD Brain and Tissue Bank for Developmental Disorders at
the University of Maryland. Human brain samples used in
immunohistochemistry studies were ordered from the Folio
Company. The human DNA samples from 90 different individuals
were order from Coriell Cell Repositories. Mouse brain samples
were prepared in accordance with previous studies [25,33].
Re-sequencing and assembling mRNAs and spliced ESTs
Available EST clones for FLJ33706 (Entrez GeneID: 284805),
including BC105014, BG820670, AW196294, H08894 and
AI301139, were purchased from Invitrogen CloneRanger
TM and
Figure 6. Immunohistochemistry studies of FLJ33706 protein in human brain. Results from confocal immunofluorescence imaging to
visualize FLJ33706 protein (red) in normal human cortex were shown. Neurons were marked with beta-tubulin-III (green). The nucleus was also
stained with DAPI (blue). The optimal dilution of FLJ33706 antibody was optimised based on the detection of cytoplasmic signal in brain cells. The
three rows showed results from three independent experiments.
doi:10.1371/journal.pcbi.1000734.g006
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with Sequencher software (Gene Codes Corporation, USA) using
publicly available reliable mRNAs, spliced ESTs and results from
our re-sequenced clones.
RNA isolation, cDNA synthesis, and real-time PCR
quantification
RNA isolation, cDNA synthesis, and real-time PCR were
performed as described previously [25], using glyceraldehyde-3-
phosphate dehydrogenase (Applied Biosystems) as an endogenous
control. Brain region and peripheral tissue RNAs were purchased
from Clonetech. FLJ33706 specific Fam-labelled MGB probe across
exon3 and 4 (59-TGAGCC GGG CCA CAT-39) and PCR primers
(Forward: 59-TCC CTT TAC AAA AAC TGG AAT GC-39;a n d
Reverse: 59-GCA GTG AGT CCA GCC AAG ACT-39) were
designed to detect the transcript. Relative quantity was calculated
using expression means of human leukocyte as references. Expres-
sion levels of two BDNF isoforms in human cortex were used as
references, following the protocols proposed in Liu et al [23,25].
Population genetics analysis
In order to test the functional constraint of the putative small
protein encoded by FLJ33706, we sequenced 90 human
individuals in different populations (Supplementary Table
S2). DNA samples were purchased from the Coriell Institute for
Medical Research. The FLJ33706 locus including the coding
sequence and 1 Kb flanking regions (intron or untranslated
regions) were PCR-amplified using primers designed by Oligo
(http://www.oligo.net). When necessary, we ran multiple PCR
experiments to amplify the full-length region. PCR bands were
sent to Invitrogen for sequencing. For each copy, four walking
reactions were performed. Subsequently, we used Phred, Phrap
and Consed [34,35] to assemble the FLJ33706 locus for each
individual. Single nucleotide polymorphisms (SNPs) were identi-
fied with Polyphred [36] and Polyscan [37]. Specifically,
homozygous or heterozygous SNPs were called by Polyphred
first. We retained those highly reliable SNPs with Polyphred score
of 99. For SNPs with a score lower than 99, we retained them only
if they were also identified by Polyscan. We used DnaSP v4.50
[38] to calculate the statistics of polymorphisms. We calculated the
probability of the number of observed segregation sites in
nonsynonymous sites on a hypothetical h (e.g. the one in
synonymous sites) by following the recursive equations [24]:
Pn s ðÞ ~
X s
i~0
Pn{1 s{i ðÞ Qn i ðÞ
Qn i ðÞ ~
lh
lhzn{1
   i n{1
lhzn{1
Where, l, n and s are defined as the length of region of interest,
the number of alleles and the number of segregation sites,
respectively. Q n(i) indicates the probability that i mutations occur
when there are n ancestral lineages, while Pn(s) indicates the
probability that s sites segregate in a sample of n individuals.
Re-analysis of rhesus monkey microarray data
We found in Affymetrix Rhesus Macaque Genome Array a
probeset MmugDNA.22336.1.S1 for the orthologous locus of
FLJ33706. We also found a GEO [22] dataset, GSE7094, which
profiled five tissues (cortex, fibroblast, pancreas, testis and thymus)
in a rhesus monkey with six replicates for each sample [39]. We
downloaded GSE7094 raw array files from NCBI GEO database
[22]. We used R and Bioconductor [40] platform to handle this
data. Specifically, we used GCRMA [41] to do background
subtraction, normalization and probe summarization, and Micro-
array Suite, version 5.0 (MAS5; Affymetrix) to call presence or
absence.
Expression of FLJ33706 recombination protein in E. coli
We expressed FLJ33706 recombination protein in E. coli
expression strain. The full-length coding region of FLJ33706 was
obtained by PCR amplification using an isolated human genomic
library as the template. The PCR products were ligated by T4
DNA ligase and the resulting full-length fragment was sub cloned
into the pET-28a expression vector with Poly His tag. The
resulting recombinant plasmids were verified by DNA sequencing,
followed by transformation into the E. coli expression strain BL21
(DE3). E. coli samples before and after the transformation were
prepared for Western blot assays.
FLJ33706 antiserum, brain sample preparation, and
Western blot analyses
A 17-amino-acid peptide with sequence CTSKAQRVH-
PQPSHQRQ that corresponded to the unique residuals 68–83
of FLJ33706 putative protein was synthesized (cystine was added
to conjugate to keyhole limpet hemocyanin) and used to immunize
rabbits (Genemed Synthesis, Inc., San Antonia, TX, USA). The
peptide sequence is highly antigenic and lacks detectable
homologues in any mammalian genomes based on BLASTP.
The FLJ33706-specific anti-serum was produced in a favourable
animal after initial and boosting immunizations. Protein levels
were quantitated using Bradford assays and 50 mg protein aliquots
of supernatant were electrophoresed using 10% SDS-polyacryla-
mide gels and Western blot analysis was performed as described
previously [25]. FLJ33706 anti-serum that was diluted 1:5000 and
the pre-immune serum that was diluted with 1:5000 were used to
replace anti-FLJ33706 serum. The synthetic peptide (100 mg/ml)
was incubated with primary antiserum that had been pre-absorbed
2 h at room temperature for the competition assay [25]. Western
blot assays with E. coli expressed FLJ33706 recombination protein
(with His-Tag) were also introduced to evaluate the specificity of
FLJ33706 antibody, in which anti-FLJ33706 and anti-His tag was
diluted at 1:5000 and 1:500, respectively.
Immunohistochemistry
Immunohistochemistry study of FLJ33706 in human brain
cortex was performed as previously described [42]. Antiserum of
FLJ33706 is produced as mentioned above (1:400), and antibody
against beta-tubulin III was ordered from Sigma (1:200).
Supporting Information
Table S1 Quantification of FLJ33706 mRNA levels
Found at: doi:10.1371/journal.pcbi.1000734.s001 (0.07 MB
DOC)
Table S2 Population distribution of 90 individuals used in
population genetics study
Found at: doi:10.1371/journal.pcbi.1000734.s002 (0.03 MB
DOC)
Figure S1 The DNA segment where FLJ33706 is located
emerged in the eutherian mammals. For the chromsome region
of FLJ33706, the 44-way vertebrate syntenic genome-alignment
tracks of the UCSC browser were shown. The alignments suggest
that the DNA segment where FLJ33706 is located emerged in the
Human-Specific de novo Protein-Coding Gene
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ranging from marsupials to lamprey.
Found at: doi:10.1371/journal.pcbi.1000734.s003 (0.43 MB TIF)
Figure S2 Multiple sequencing reads support that chimpanzee
share the ancestral status of the disablers of FLJ33706 proper open
reading frame. The figure showed that a stop codon (TAG) in
chimpanzee is supported by six reads, thus unlikely to be caused by
sequencing errors.
Found at: doi:10.1371/journal.pcbi.1000734.s004 (0.04 MB TIF)
Figure S3 Sliding window analysis of nucleotide diversity. The
boxes above the bottom line mark the location of exons (Exon 2, 3
and 4) by scale. ‘ATG’ and ‘TAG’ indicate the start codon and
stop codon respectively. The yellow boxes below the bottom line
show the repeat elements annotated by UCSC genome browser.
As the figure shows, all four notable polymorphism peaks concur
with non-CDS regions such as introns or 39 UTR. If we consider
that repeat elements might help to facilitate recombination and
thus increase pi, the constraint of CDS is even more pronounced
since almost the whole first coding exon is covered by a repeat
element.
Found at: doi:10.1371/journal.pcbi.1000734.s005 (0.09 MB TIF)
Figure S4 Significantly higher FLJ33706 mRNA expression
levels were detected in human AD brains. The transcript
expression level of FLJ33706 in 20 Alzheimer’s disease (AD)
brains and 18 normal brains were tested. The transcript expression
level of FLJ33706 in AD brains is significantly elevated in
Alzheimer’s disease (AD) brains (Mann Whitney Test p=0.0273).
CNT: normal brain tissues; AD: Alzheimer’s disease brain
tissues.
Found at: doi:10.1371/journal.pcbi.1000734.s006 (0.13 MB TIF)
Figure S5 Introns 2 and 3 of FLJ33706 are enriched with fast-
evolving nucleotides. We downloaded phyloP conservation score
based on placental mammal genome alignment from UCSC table
browser and then made a smoothed plot with Geneplotter package
in R. Positive score means constraint, while negative score
indicates positive selection. The pink box marks a fast-evolving
peak, which concurs with the second and third introns.
Found at: doi:10.1371/journal.pcbi.1000734.s007 (0.69 MB TIF)
Acknowledgments
We thank Drs. Juan Troncoso and Olga Pletnikova from Department of
Pathology, Johns Hopkins Medical School for brain tissue samples. We
thank Drs. Maynard Olson, Gang Pei, Wei Peng, Jingjing Wang, Michael
Walker, and Junlin Teng for helpful suggestions. We thank Emily Wentzel
for copyediting of the manuscript.
Author Contributions
Conceived and designed the experiments: Chuan-Yun Li, George R Uhl,
Qing-Rong Liu, Liping Wei. Performed the experiments: Chuan-Yun Li,
Zhanbo Wang, Yan Zhang, Chunmei Cao, Ping-Wu Zhang, Shu-Juan Lu,
Xiao-Mo Li, Quan Yu, Xiaofeng Zheng, Quan Du. Analyzed the data:
Chuan-Yun Li, Yong Zhang. Wrote the paper: Chuan-Yun Li, Yong
Zhang, Qing-Rong Liu, Liping Wei. Performed most of the experiments:
Chuan-Yun Li. Conceived the idea: Chuan-Yun Li, Liping Wei.
References
1. Ohno S (1970) Evolutionby gene duplication. Berlin: Springer-Verlag.
2. Leister D (2004) Tandem and segmental gene duplication and recombination in
the evolution of plant disease resistance gene. Trends Genet 20: 116–122.
3. Marques AC, Dupanloup I, Vinckenbosch N, Reymond A, Kaessmann H
(2005) Emergence of young human genes after a burst of retroposition in
primates. PLoS Biol 3: e357.
4. Long M, Langley CH (1993) Natural selection and the origin of jingwei, a
chimeric processed functional gene in Drosophila. Science 260: 91–95.
5. Wang W, Zhang J, Alvarez C, Llopart A, Long M (2000) The origin of the
Jingwei gene and the complex modular structure of its parental gene, yellow
emperor, in Drosophila melanogaster. Mol Biol Evol 17: 1294–1301.
6. Begun DJ, Lindfors HA, Kern AD, Jones CD (2007) Evidence for de novo
evolution of testis-expressed genes in the Drosophila yakuba/Drosophila erecta
clade. Genetics 176: 1131–1137.
7. Cai J, Zhao R, Jiang H, Wang W (2008) De novo origination of a new protein-
coding gene in Saccharomyces cerevisiae. Genetics 179: 487–496.
8. Chen ST, Cheng HC, Barbash DA, Yang HP (2007) Evolution of hydra, a
recently evolved testis-expressed gene with nine alternative first exons in
Drosophila melanogaster. PLoS Genet 3: e107.
9. Levine MT, Jones CD, Kern AD, Lindfors HA, Begun DJ (2006) Novel genes
derived from noncoding DNA in Drosophila melanogaster are frequently X-
linked and exhibit testis-biased expression. Proc Natl Acad Sci U S A 103:
9935–9939.
10. Toll-Riera M, Bosch N, Bellora N, Castelo R, Armengol L, et al. (2008) Origin
of primate orphan genes: a comparative genomics approach. Mol Biol Evol.
11. Knowles DG, McLysaght A (2009) Recent de novo origin of human protein-
coding genes. Genome Res 19: 1752–1759.
12. Siepel A (2009) Darwinian alchemy: Human genes from noncoding DNA.
Genome Res 19: 1693–1695.
13. Uhl GR, Liu QR, Drgon T, Johnson C, Walther D, et al. (2007) Molecular
genetics of nicotine dependence and abstinence: whole genome association using
520,000 SNPs. BMC Genet 8: 10.
14. Uhl GR, Liu QR, Drgon T, Johnson C, Walther D, et al. (2008) Molecular
genetics of successful smoking cessation: convergent genome-wide association
study results. Arch Gen Psychiatry 65: 683–693.
15. Saccone SF, Pergadia ML, Loukola A, Broms U, Montgomery GW, et al. (2007)
Genetic linkage to chromosome 22q12 for a heavy-smoking quantitative trait in
two independent samples. Am J Hum Genet 80: 856–866.
16. Wang D, Ma JZ, Li MD (2005) Mapping and verification of susceptibility loci for
smoking quantity using permutation linkage analysis. Pharmacogenomics J 5:
166–172.
17. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, et al. (2001) Initial
sequencing and analysis of the human genome. Nature 409: 860–921.
18. UniProt_Consortium (2010) The Universal Protein Resource (UniProt) in 2010.
Nucleic Acids Res 38: D142–148.
19. Karolchik D, Kuhn RM, Baertsch R, Barber GP, Clawson H, et al. (2008) The
UCSC Genome Browser Database: 2008 update. Nucleic Acids Res 36:
D773–779.
20. Wheeler DL, Barrett T, Benson DA, Bryant SH, Canese K, et al. (2008)
Database resources of the National Center for Biotechnology Information.
Nucleic Acids Res 36: D13–21.
21. Wu M, Li L, Sun Z (2007) Transposable element fragments in protein-coding
regions and their contributions to human functional proteins. Gene 401:
165–171.
22. Barrett T, Troup DB, Wilhite SE, Ledoux P, Rudnev D, et al. (2009) NCBI
GEO: archive for high-throughput functional genomic data. Nucleic Acids Res
37: D885–890.
23. Liu QR, Walther D, Drgon T, Polesskaya O, Lesnick TG, et al. (2005) Human
brain derived neurotrophic factor (BDNF) genes, splicing patterns, and
assessments of associations with substance abuse and Parkinson’s Disease.
Am J Med Genet B Neuropsychiatr Genet 134B: 93–103.
24. Hudson RR (1990) Oxford Surveys in Evolutionary Biology 7, chapter Gene
genealogies and the coalescent process. Oxford.
25. Gong JP, Liu QR, Zhang PW, Wang Y, Uhl GR (2005) Mouse brain
localization of the protein kinase C-enhanced phosphatase 1 inhibitor KEPI
(kinase C-enhanced PP1 inhibitor). Neuroscience 132: 713–727.
26. Varki A, Altheide TK (2005) Comparing the human and chimpanzee genomes:
searching for needles in a haystack. Genome Res 15: 1746–1758.
27. Knowles DG, McLysaght A (2009) Recent de novo origin of human protein-
coding genes. Genome Research 19: 1752–1759.
28. Siepel A (2009) Darwinian alchemy: Human genes from noncoding DNA.
Genome Research 19: 1693–1695.
29. Hartl DL, Clark AG (2007) Human population genetics. Principles of population
genetics. Fourth ed: Sinauer Associates, Inc. Publishers.
30. Cooper GM, Stone EA, Asimenos G, Green ED, Batzoglou S, et al. (2005)
Distribution and intensity of constraint in mammalian genomic sequence.
Genome Res 15: 901–913.
31. Wulczyn FG, Smirnova L, Rybak A, Brandt C, Kwidzinski E, et al. (2007) Post-
transcriptional regulation of the let-7 microRNA during neural cell specification.
Faseb J 21: 415–426.
32. Vallender EJ, Mekel-Bobrov N, Lahn BT (2008) Genetic basis of human brain
evolution. Trends Neurosci 31: 637–644.
33. Liu QR, Lu L, Zhu XG, Gong JP, Shaham Y, et al. (2006) Rodent BDNF genes,
novel promoters, novel splice variants, and regulation by cocaine. Brain Res
1067: 1–12.
Human-Specific de novo Protein-Coding Gene
PLoS Computational Biology | www.ploscompbiol.org 10 March 2010 | Volume 6 | Issue 3 | e100073434. Ewing B, Green P (1998) Base-calling of automated sequencer traces using
phred. II. Error probabilities. Genome Res 8: 186–194.
35. Gordon D, Abajian C, Green P (1998) Consed: a graphical tool for sequence
finishing. Genome Res 8: 195–202.
36. Nickerson DA, Tobe VO, Taylor SL (1997) PolyPhred: automating the
detection and genotyping of single nucleotide substitutions using fluorescence-
based resequencing. Nucleic Acids Res 25: 2745–2751.
37. Chen K, McLellan MD, Ding L, Wendl MC, Kasai Y, et al. (2007) PolyScan: an
automatic indel and SNP detection approach to the analysis of human
resequencing data. Genome Res 17: 659–666.
38. Rozas J, Sanchez-DelBarrio JC, Messeguer X, Rozas R (2003) DnaSP, DNA
polymorphism analyses by the coalescent and other methods. Bioinformatics 19:
2496–2497.
39. Duan F, Spindel ER, Li YH, Norgren RB, Jr. (2007) Intercenter reliability and
validity of the rhesus macaque GeneChip. BMC Genomics 8: 61.
40. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, et al. (2004)
Bioconductor: open software development for computational biology and
bioinformatics. Genome Biol 5: R80.
41. Wu Z, Irizarry R, Gentleman R, Murillo FM, Spencer F (2004) A Model Based
Background Adjustment for Oligonucleotide Expression Arrays. Johns Hopkins
University Dept of Biostatistics Working Paper Series.
42. Peng W, Zhang Y, Zheng M, Cheng H, Zhu W, et al. Cardioprotection by
CaMKII-deltaB is mediated by phosphorylation of heat shock factor 1 and
subsequent expression of inducible heat shock protein 70. Circ Res 106:
102–110.
Human-Specific de novo Protein-Coding Gene
PLoS Computational Biology | www.ploscompbiol.org 11 March 2010 | Volume 6 | Issue 3 | e1000734